Pelican Cancer Foundation

Pelican Cancer Foundation

  • Facebook
  • Instagram
  • Twitter
  • YouTube
DONATE NOW
  • Home
  • About Us
    • About us
    • What we do
      • Bowel cancer
      • Colorectal Liver Metastases
      • Pseudomyxoma peritonei
      • Our Research
      • Our achievements
      • What’s next?
    • Who we are
      • Our board
      • Our team
      • Pelican Patrons
      • Job opportunities
    • Support Us
    • Keep in touch
    • Our annual accounts
  • Workshops
    • Pelican IMPACT
      • IMPACT – Completion & Evaluation
      • Workshops
      • IMPACT – Online resources
      • IMPACT – Partners and Sponsors
    • SPECC
      • SPECC – Completion & Evaluation
      • Workshops
      • SPECC – Online resources
      • SPECC – Partners and Sponsors
    • LOREC
    • TIPTOP
      • Workshops
      • TIPTOP – Online resources
      • Bob’s story (prostate cancer)
      • Andrew’s story (prostate cancer)
      • Alan’s story (prostate cancer)
      • Raymond’s story (prostate cancer)
    • What clinicians say about our courses
    • Faculty
    • Our sponsors
    • Become a sponsor
    • Request a course or topic
    • Give us feedback
    • Previous courses
  • Films
  • Research
    • Research strategy
    • Bowel cancer research
      • POLARS
      • MERCURY 2 (Low Rectal Cancer Study)
      • Deferral of surgery study
      • TATME
      • IMPRESS
      • TRIGGER
      • Papers of interest
      • Timing of surgery
      • AMSOEC
      • MINSTREL
      • Completed research
        • Perineal wound healing registry
        • Beyond TME
        • Validation of the LARS score
        • MARVEL: Evaluation of EMVI positive rectal cancer
        • FLEX
        • TME Physical Simulation Model
        • Total Mesorectal Excision (TME)
        • MERCURY research programme
    • Liver cancer research
      • Completed research
        • EORTC studies
      • SERENADE
      • Papers of interest
    • Peritoneal malignancy research
      • Colorectal Peritoneal Malignancy Database
      • Pseudomyxoma Pathology Atlas
    • Previous Research Areas
      • Prostate Cancer Research
        • Prostate cancer
        • Focal therapy and HIFU research
        • MRI research for prostate cancer
        • Prostate cancer colloquiums
        • FORECAST
        • Trachtomap
        • Papers of interest
      • Bladder cancer research
        • Bladder cancer
        • Papers of interest
    • Peer reviewers
    • Clinical trials
    • Information for researchers
      • Peer review process
      • Research review panel
      • Research Grant Application Guidance Notes
      • Terms and conditions of grants
      • Animals in medical research
      • Research costs
    • Surgical videos
  • For Patients
    • Patient stories
      • Anthony’s story (bowel cancer)
      • Elena’s story (bowel cancer)
      • Terry’s story (liver cancer)
      • Derrick’s story (liver cancer)
      • Alex’s story (colorectal cancer)
      • Cheryll’s story (rectal cancer)
      • Eileen’s story
      • Richard’s story – irrigation
      • Tom’s story – complete response
      • Advanced metastatic bowel cancer
    • What is an MDT?
      • What an MRI reveals
      • Reporting cancer outcomes
    • Bowel cancer
      • Our bowel cancer team
      • About bowel cancer treatment – TME
      • April – Bowel Cancer Awareness Month
      • Low rectal cancer
      • Complete response to chemoradiotherapy in rectal cancer
      • Frequently asked questions about bowel cancer
      • Irrigation for colostomies
      • A patient’s advice
      • Symptom checker
      • Bowel cancer – useful contacts
    • Liver cancer
      • Our liver cancer team
      • About liver cancer treatment
      • Interventional radiology
      • Liver cancer – frequently asked questions
      • Carcinoid and neuroendocrine tumours
      • Liver cancer – want to read more?
    • Pseudomyxoma peritonei
    • Getting a second opinion
    • Clinical trials
      • Current clinical trials
    • Tell us your story
    • Still got questions about cancer?
    • Links
  • Support us
    • Make a donation
      • Make a donation
      • Why donate to Pelican?
      • Donate shares
      • Donate in memory
      • How your donations are spent
    • Fundraising
      • Our fundraisers
      • Fundraising ideas
      • Fundraising challenges
      • Fundraising resources
      • Our events
    • Leaving a Legacy
    • Volunteering Opportunities
    • Could you host a Pelican Talk?
    • Become a Corporate Charity Partner
    • Pelican Film Society
  • Shop
  • Events
  • Contact us

EORTC studies

Patient reported outcomes (PROs) are measures of health that come directly from patients and have not been interpreted by an observer. They are playing an increasing role in the evaluation of healthcare as they often differ from the observations of others. They provide information about the patient’s experience of treatment that may not be recorded using only standard outcomes. For cancer patients the most common questionnaire is called the EORTC QLQ-C30. This can be supplemented by additional disease-specific modules to increase sensitivity and content validity.

Pelican has supported studies that develop and validate disease-specific modules for the EORTC QLQ-C30, more detail can be found below.

Validation of a disease-specific EORTC module for colorectal liver metastases

International clinical and psychometric validation of a PROM for colorectal liver metastases: the EORTC QLQ-LMC2.

A module for patients with colorectal liver metastases including 21 questions (addressing nutritional problems, fatigue, pain and emotional issues) has been developed. It is called the QLQ-LMC21.

This international study, including oncologists and statisticians from the UK, France, Germany and Norway, aimed to validate the module. 356 patients, either undergoing hepatectomy or primary palliative treatment, completed the QLQ-C30 and the QLQ-LMC21 before and three months after treatment.

The study found that the additional questionnaire was completed easily by patients and that it measured several aspects of health that were not covered in the original questionnaire. This resulted in the validation of the QLQ-LMC21.

Read the abstract from the British Journal of Surgery.

Validation of a disease-specific EORTC module for G.I.-related neuroendocrine tumours

Clinical and Psychometric Validation of a Disease-Specific Questionnaire Module in Assessing the Quality of Life of Patients with G.I.-related Neuroendocrine Tumours.

A module for patients with gastro-intestinal related neuroendocrine tumours (G.I. NETs) has been developed with 21 questions. It is called the QLQ-G.I.NET21.

This international study, including 10 UK and 9 international centres, aimed to carry out a phase 4 validation study to test the structure, validity and reliability of the QLQ-G.I.NET21. It also aimed to assess the quality of life of the patients using the QLQ-C30 and the QLQ-G.I.NET21 before and after treatment.

The module has been found to be a valid and responsive tool for assessing quality of life in gut, pancreas and liver neuroendocrine tumours.

Read the abstract from the British Journal of Cancer.

Development of a disease-specific EORTC module for cholangiocarcinoma and gall bladder cancer

Development of a questionnaire EORTC module to measure the Quality of Life in patients with Cholangiocarcinoma and Gall Bladder Cancer.

A module for patients with colorectal liver metastases has been developed, called the QLQ-LMC21. A module for patients with pancreatic cancer has also been developed, called the QLQ-PAN26.

This international study, including invesigators from the UK, Taiwan, Italy and Germany, aimed to test the questions and issues of the LMC21 and PAN26 in cholangiocarcinoma patients and assess whether either or both are adequate. If it was found that neither alone were adequate then the EORTC protocol would be used to develop a new module questionnaire for cholangiocarcinoma patients.

Following interviews with patients and healthcare professionals 5 questions from PAN26, 15 from LMC21 and 3 extra questions were used to create a 21 item module. This is the disease-specific module for patients with cholangiocarcinoma and gall bladder cancer.

Read the abstract from the British Journal of Cancer.

Pelican Cancer Foundation Follow

Driving innovation and advancing surgery to help patients live well, for longer.

Pelican_Cancer
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
28 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1597119096096784384 Retweet on Twitter 1597119096096784384 2 Like on Twitter 1597119096096784384 2 Twitter 1597119096096784384
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
26 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1596393313757642752 Retweet on Twitter 1596393313757642752 1 Like on Twitter 1596393313757642752 1 Twitter 1596393313757642752
pelican_cancer Pelican Cancer Foundation @pelican_cancer ·
25 Nov

👇 Available now - http://pelicancancervideos.org
🎥Complexity and decision making for patients with low rectal cancer

Mr Mark Gudgeon, Professor Heald & Mr Moran
@MGudgeon @ProfessorHeald @Brendan92855812

Reply on Twitter 1596159243203350528 Retweet on Twitter 1596159243203350528 2 Like on Twitter 1596159243203350528 5 Twitter 1596159243203350528
Load More...

To view our privacy policy - click here.
Registered charity no: 1141911

Copyright © 2023 · Outreach Pro Theme on Genesis Framework · WordPress · Log in